TransMedics Group (NASDAQ:TMDX) Receives "Hold" Rating from Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reissued by stock analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports.

Several other analysts have also recently issued reports on TMDX. Oppenheimer increased their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Piper Sandler restated an "overweight" rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $128.70.

TransMedics Group Stock Performance

TMDX traded up $1.07 on Tuesday, hitting $129.81. The company's stock had a trading volume of 789,937 shares, compared to its average volume of 1,358,819. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The firm has a market cap of $4.39 billion, a P/E ratio of 138.10 and a beta of 2.10. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company's 50 day simple moving average is $97.54 and its 200-day simple moving average is $79.14.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same period last year, the company earned $0.35 earnings per share. The business's revenue for the quarter was up 48.2% on a year-over-year basis. Analysts forecast that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,732 shares of company stock valued at $1,416,710 over the last three months. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. purchased a new stake in TransMedics Group during the 1st quarter valued at $25,000. Smartleaf Asset Management LLC raised its holdings in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after purchasing an additional 135 shares during the period. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the fourth quarter valued at about $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter worth approximately $33,000. Finally, Quarry LP lifted its stake in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.